ZURICH, Switzerland, February 27 /PRNewswire/ -- Solianis sees its Multi-Sensor Technology as a promising approach to continuous non-invasive glucose monitoring. Professor Marc Donath, member of the Solianis Scientific Advisory Board and Professor for endocrinology and diabetology at the University Hospital in Zurich, Switzerland, has supervised multiple trials during the last years at the hospital. These trials have shown that Solianis' multi-sensor technology operates under various conditions to track glucose changes in the human body. Today, in their daily lives, patients are wearing a first configuration of the device to test its applicability.
Professor Lutz Heinemann, Chairman of the Solianis Scientific Advisory Board, CEO of Profil Institut für Stoffwechselforschung GmbH, is very pleased with the results of the latest studies. "Solianis has taken a great step forward in its clinical development towards the market introduction of a continuous, non-invasive glucose monitor" said Professor Heinemann. Professor Donath added that "with the current level of reliability that the device has shown in the studies, Solianis will be able to support patients with diabetes in daily disease management."
Mario Stark, the CEO of Solianis Monitoring AG pointed out that "these results show that the intensive work over the last years has brought us closer to success. The thorough tests started in November 2007 of multi-sensor technology in daily life, will give us important information about the next steps in the development and implementation of the continuous non-invasive glucose monitor." He was cautious with setting a date for the market introduction but was confident that patients with diabetes very soon should be able to rely on Solianis' multi-sensor technology to manage their diabetes.
Contact: Mario Stark, CEO, Tel.: +41-44-306-80-40, Mobile: +41-79-542-88-74, E-Mail: email@example.com